Showing results (11-20 of 122) with videos related to
Sort By:
Pageof 13
Acta Ophthalmologica Scandinavica. Supplement|November 1, 2000
An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge modelM B Abelson, D L WelchOphthalmology|November 1, 1988
Levocabastine. Evaluation in the histamine and compound 48/80 models of ocular allergy in humansM B Abelson, L M SmithAnnals of Ophthalmology|March 1, 1988
Importance of limbal examination in ocular allergic diseaseS I Butrus, M B AbelsonThe Journal of Allergy and Clinical Immunology|January 8, 2005
Allergic conjunctivitis: update on pathophysiology and prospects for future treatmentSanta Jeremy Ono, Mark B AbelsonCurrent Medical Research and Opinion|February 11, 2005
Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge modelMark B Abelson, Jack V GreinerAmerican Journal of Ophthalmology|February 1, 1981
Animal and human ocular surface response to a topical nonimmune mast-cell degranulating agent (compound 48/80)I J Udell, M B AbelsonActa Ophthalmologica Scandinavica. Supplement|May 25, 1999
The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge modelM B Abelson, R Q LanierClinical Therapeutics|April 16, 2002
A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge modelMark B Abelson, Allen P KaplanClinical and Experimental Rheumatology|December 17, 2008
Mortality in rheumatoid arthritis: 2008 updateT Sokka, B Abelson, T PincusExpert Opinion on Drug Metabolism & Toxicology|April 25, 2008
Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosingMark B Abelson, Paul J GomesPageof 13